Romidepsin (FK228) target focal adhesion kinase (FAK) expression in lung fibrosis

Aims: Investigate the effect of the HADCI, FK228, on IPF fibroblasts differentiation and migration. Background: IPF is the most severe form of interstitial pneumonias with an unknown aetiology and without a successful therapy. Recent studies have demonstrated that HDAC inhibitors are good candidate for the treatment of fibrosis. These enzymes are specifically druggable, providing important therapeutic targets for IPF. Methods: The expression of FAK in IPF fibroblasts during FK228 treatment was assessed by western blot and real time PCR. The migration ability of IPF fibroblasts was assessed by scratch wound assay and transwell migration assay. Results: During FK228 treatment, FAK protein levels are down regulated in IPF fibroblasts resulting in the reduction of cell motility. Conclusions: FK228 is a good candidate for the treatment of IPF exhibiting a potent inhibition of fibroblast migration. By target FAK expression, FK228 could reduce fibroblasts dissemination resulting in a slower progression of lung fibrosis.